mRNA Therapeutics for Propionic Acidemia via Lipid Nanoparticle Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for propionic acidemia (PA) are inadequate, leading to significant morbidity and mortality due to the accumulation of propionyl-CoA and its metabolites, causing metabolic acidosis and hyperammonemia, with no approved therapies in the U.S. beyond dietary restrictions and limited medical management.
Innovation Solution
The development of mRNA therapeutics that deliver modified nucleotides encoding PCCA and/or PCCB to facilitate the intracellular synthesis of functional propionyl-CoA carboxylase, utilizing lipid nanoparticles for efficient delivery and minimizing immune activation, thereby increasing enzyme activity and reducing toxic metabolite levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mRNA therapeutics are administered to increase PCC activity, then enzyme function is improved, but immune activation may occur
Solution Approach 1:
The patent modifies nucleotide parameters within the mRNA sequence, specifically optimizing the codon usage and nucleotide composition to reduce immune recognition while maintaining protein translation efficiency. This involves changing the chemical parameters of the nucleotides (e.g., using modified bases like pseudouridine) to alter how the immune system perceives the mRNA without affecting the encoded protein sequence.
2Object-generated harmful factors
If dietary restrictions are imposed to manage PA, then toxic metabolite accumulation is reduced, but quality of life and nutritional intake are limited
Solution Approach 1:
The mRNA therapeutics enable the patient's own cells to produce functional PCC enzyme, allowing the body to self-correct the metabolic defect without requiring external dietary management. The endogenous enzyme production eliminates the need for lifelong dietary restrictions, as the therapeutic directly addresses the root cause of metabolite accumulation.
3Reliability
If liver transplant is performed to treat severe PA, then enzyme deficiency is corrected, but surgical risks and complications increase
Solution Approach 1:
The mRNA acts as an intermediary that delivers the genetic instructions for PCC enzyme production without requiring organ replacement. Instead of transplanting a liver (the complex organ), the patent uses mRNA as a simpler mediator to provide the missing enzymatic function, avoiding surgical risks while achieving the same therapeutic goal.
Data Source
AI summary
This disclosure relates to mRNA therapy for the treatment of propionic acidemia (PA). mRNAs for use in the invention, when administered in vivo, encode human propionyl-CoA carboxylase alpha (PCCA) and/or human propionyl-CoA carboxylase beta (PCCB), and isoforms thereof, functional fragments thereof, and fusion proteins comprising PCCA and/or PCCB. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of propionyl-CoA carboxylase (PCC) expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of disease-associated toxic metabolites associated with deficient PCCA or PCCB activity, in subjects.